Probiotics UK Insights – Your Guide to Gut Health & Wellbeing – Tagged "VSL3 clinical studies"

Clinical Gut Health Intelligence

Providing the latest research on the original De Simone Formulation (CDS22) and high-potency microbiome support in the UK. All content is clinically reviewed to ensure accuracy for patients and healthcare professionals.

The UK’s Specialist Hub for Probiotic Evidence & Gut Health Research

Welcome to the Probiotics UK & Gut Health Knowledge Hub, the central resource for evidence-based research on the original De Simone Formulation (CDS22). This hub provides UK readers, patients, and healthcare professionals with clinical guides, high-potency strain comparisons, and the latest gastroenterology updates dispatched from our Lancashire facility.

Probiotic.co.uk publishes UK-focused guides on probiotics, microbiome science, and digestive health. Articles reference guidance from the NHS, UK Food Standards Agency (FSA) regulations on food supplements, and peer-reviewed clinical research in gastroenterology and microbiome science where relevant.


Our editorial focus includes probiotics for IBS, ulcerative colitis, pouchitis, antibiotic-associated diarrhoea, microbiome restoration after antibiotics, and general digestive health support. Many guides discuss the Original De Simone Formulation (CDS22), a high-strength probiotic formulation studied in more than 200 peer-reviewed scientific publications.


Content is written for UK readers and reflects UK supplement regulations, NHS clinical pathways, and real-world patient questions commonly seen in gastroenterology practice. From our cold-chain facility in Chorley, Lancashire, we monitor developments in gut microbiome research and translate emerging science into clear guidance for clinicians, pharmacists, and informed consumers across the UK.

Probiotic.co.uk publishes independent, evidence-led guides for UK readers on probiotics, gut health, and food supplements. Every guide cites named published research, references NHS and FSA guidance where relevant, and is written specifically for the UK market.

CDS22 & De Simone Formulation
Condition & General Guides
Comparison Guides
Supplement Guides

Reference guides · Educational content · Updated regularly

AGA pouchitis guideline Barnes 2024 CDS22-formula clinical guidelines probiotic UK clinical probiotics uk De Simone Formulation De Simone Formulation evidence gut health UK pouchitis probiotic VSL3 clinical studies
What the Clinical Guidelines Say About the De Simone Formulation: The AGA Pouchitis Guideline Explained (UK)

By Darren Grant on Jun 28, 2026

Barnes et al. (American Gastroenterological Association, Gastroenterology 2024;166(1):59-85, PMID 38128971) state that the evidence favouring probiotics for preventing recurrent pouchitis is limited to the De Simone Formulation, based on three randomised trials showing an 87% lower relapse risk over 12 months (RR 0.17; 95% CI 0.09-0.34; low certainty of evidence). This UK reference guide explains exactly what the AGA pouchitis guideline says, how the De Simone Formulation differs from the post-2016 VSL#3 brand (Fourth Circuit false-advertising ruling; ECCO and ESPEN attribution clarifications), the verified PMIDs, and how the formulation is supplied today as CDS22-formula (8 NCIMB strains, 450 billion CFU, £19.95 per 12-sachet pack), a food supplement under FSA rules, not a medicine, cold-chain delivered across the UK by Probiotic.co.uk.

Read more
v=
Clinical Reference
Key Facts: The Original De Simone Formulation
  • CDS22 contains 8 strains from the original De Simone formulation developed by Professor Claudio De Simone
  • The formulation has been studied in over 80 peer-reviewed publications for IBS, ulcerative colitis, and pouchitis
  • Referenced in ECCO IBD guidelines and American Gastroenterological Association (AGA) clinical guidance
  • The original formulation was previously marketed in the UK as VSL#3 and Vivomixx
  • Following a 2016 US court ruling, the De Simone IP was separated from the VSL#3 brand
  • CDS22 is the only UK product carrying the original 8-strain formula at 450 billion CFU per sachet
  • Available exclusively in the UK from Probiotic.co.uk, dispatched from Chorley, Lancashire
Start Here
Core Clinical Guides
VSL#3 Alternative UK: The Original De Simone Formulation is Now CDS22 →
CDS22 contains the original 8-strain De Simone formulation used in peer-reviewed trials for IBS and ulcerative colitis. Available exclusively in the UK from Probiotic.co.uk.
De Simone Formulation UK: Complete Legal Timeline, Strains & Availability →
The De Simone formulation comprises 8 specific strains separated from VSL#3 via US and Italian court rulings in 2016. CDS22 is the current authorised UK product.
CDS22 vs VSL#3: Original De Simone Formulation Comparison (UK Guide) →
The current VSL#3 was changed following a 2016 US court ruling. CDS22 contains the original 8 strains at 450 billion CFU with over 80 peer-reviewed trials.
Best Probiotic for UC, IBS & Pouchitis: Evidence-Based UK Guide →
The De Simone formulation is the only probiotic referenced in ECCO IBD guidelines for ulcerative colitis and pouchitis, with remission data from Gionchetti 2000 and Mimura 2004.
The Ultimate Guide to Probiotics in the UK →
Named clinical trials (Hill 2014, Ford 2018, Gionchetti 2000), FSA regulatory framework, five-point evaluation checklist, strain types, CFU guidance and FAQ.